Aisling Capital Management LP
CIK 1766721 · View on SEC EDGAR ↗
- Portfolio value
- $471.6M
- Positions
- 14
- As of
- June 30, 2026
Portfolio value QoQ: -1.0% 13F does not disclose cash
- Top 10 holdings weight
- 98.96%
- Top 25 holdings weight
- 100.00%
- Positions above 1%
- 6
- Effective number of positions
- 1.9
Based on 13F long-equity holdings only (cash, bonds, shorts not disclosed)
Turnover Q2 2026: 0.4% Est. buys $1,882,500 · sells $37,240,000
Median holding: 4.5 quarters Tracked Q4 2024–Q2 2026 · 70.0% still held
- New positions
- 1
- Increased
- 0
- Decreased
- 1
- Closed
- 1
On this page
- Performance vs S&P How this manager's 13F portfolio performed against the S&P 500.
- Sector breakdown How the portfolio splits across market sectors.
- Portfolio Every stock this institution reports holding, from its latest 13F.
- Biggest new bets Brand-new positions opened in the latest quarter.
- Top moves The biggest position increases and decreases this quarter.
- Exited positions Positions the manager fully sold out of last quarter.
Performance vs S&P 500
Annualized: +97.5% · S&P 500: +18.0%
Approximates a buy-and-hold portfolio built from quarterly SEC 13F snapshots. Excludes cash, short positions, options/derivatives, and non-13(f) securities — reflects the disclosed long-equity book only, not total fund AUM. SEC filing lag is up to 45 days; this is not a real-time-copyable timing.
Priceable coverage: 96.6% · Options excluded: 0.0%
Sector breakdown
Full portfolio 14 positions
| Type | Streak | 8Q trend | |||||
|---|---|---|---|---|---|---|---|
| BBIO BridgeBio Pharma, Inc. - Common Stock | $341,834,227 | 72.48% | 4,589,611 | $-36,120,286 | Down ×1 | ||
| GLUE Monte Rosa Therapeutics, Inc. - Common Stock | $37,647,069 | 7.98% | 1,555,664 | $12,056,396 | |||
| SNDX Syndax Pharmaceuticals, Inc. - Common Stock | $28,785,379 | 6.10% | 1,316,806 | $-1,975,209 | |||
| CMPS COMPASS Pathways Plc - American Depository Shares | $20,267,554 | 4.30% | 1,432,336 | $12,346,736 | |||
| BCAX Bicara Therapeutics Inc. - Common Stock | $16,891,205 | 3.58% | 568,919 | $5,575,406 | |||
| BBOT BridgeBio Oncology Therapeutics, Inc. - Common Stock | $7,757,297 | 1.64% | 1,018,018 | $-1,353,964 | |||
| SRRK Scholar Rock Holding Corporation - Common Stock | $4,236,705 | 0.90% | 77,031 | $449,861 | |||
| URGN UroGen Pharma Ltd. - Ordinary Shares | $3,974,400 | 0.84% | 108,000 | $2,032,560 | |||
| BMEA Biomea Fusion, Inc. - Common Stock | $3,011,673 | 0.64% | 2,048,757 | $-122,925 | |||
| ACRS Aclaris Therapeutics, Inc. - Common Stock | $2,298,267 | 0.49% | 434,455 | $669,061 | |||
| EPRX Eupraxia Pharmaceuticals Inc. - Common Stock | $2,148,250 | 0.46% | 325,000 | $-204,750 | |||
| VTVT vTv Therapeutics Inc. - Class A Common Stock | $1,882,500 | 0.40% | 50,000 | Up ×1 | |||
| MRKR Marker Therapeutics, Inc. - Common Stock | $478,293 | 0.10% | 325,370 | $55,312 | |||
| OKUR OnKure Therapeutics, Inc. - Class A Common Stock | $404,048 | 0.09% | 88,607 | $37,215 | |||
| No matches | |||||||
Biggest new bets
New positions opened this quarter, largest first.
| Security | Value | Shares | % of portfolio |
|---|---|---|---|
| VTVT | $1,882,500 | 50,000 | 0.40% |
Top movers (QoQ)
| Security | Action | Shares Δ | Value Δ |
|---|---|---|---|
| BBIO | Trimmed | -500K | -$36.1M |
| CMPS | Price move only | +0 | +$12.3M |
| GLUE | Price move only | +0 | +$12.1M |
| BCAX | Price move only | +0 | +$5.6M |
| URGN | Price move only | +0 | +$2.0M |
| SNDX | Price move only | +0 | -$2.0M |
| BBOT | Price move only | +0 | -$1.4M |
| ACRS | Price move only | +0 | +$669K |
| SRRK | Price move only | +0 | +$450K |
| EPRX | Price move only | +0 | -$205K |
Exited positions
Includes corporate events (mergers, delistings) — not all exits are sells
Closed positions reflect 13F reporting changes; for index managers these are often mechanical (delisting, M&A, index rebalancing), not active decisions.
| Security | Quarter | Shares before | Value before | Price since exit |
|---|---|---|---|---|
| VRNA | Dec. 31, 2025 | 615,352 | $65,664,212 | No longer tracked |
| NUVB | Dec. 31, 2025 | 2,960,659 | $10,954,438 | -21.5% |
| PSTX | March 31, 2025 | 1,043,267 | $10,015,363 | No longer tracked |
| CALC | March 31, 2026 | 521,114 | $3,434,141 | 6.5% |
| ELEV | Sept. 30, 2025 | 2,834,910 | $1,040,695 | No longer tracked |
| VIRX | March 31, 2025 | 288,571 | $46,171 | No longer tracked |